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use#LAAIn a matched case-control study, we studied the effect
of prior receipt of fluoroquinolones on isolation of three
third-generation cephalosporin-resistant gram-negative
nosocomial pathogens. Two hundred eighty-two cases with
a third-generation cephalosporin-resistant pathogen (203
with Enterobacter spp., 50 with Pseudomonas aeruginosa,
and 29 with Klebsiella pneumoniae) were matched on
length of stay to controls in a 1:2 ratio. Case-patients and
controls were similar in age (mean 62 years) and sex (54%
male). Variables predicting third-generation cephalosporin
resistance were surgery (p = 0.005); intensive care unit
stay (p < 0.001); and receipt of a β-lactam/β-lactamase
inhibitor (p < 0.001), a ureidopenicillin (p = 0.002), or a
third-generation cephalosporin (p < 0.001). Receipt of a flu-
oroquinolone was protective against isolation of a third-
generation cephalosporin-resistant pathogen (p = 0.005).
Interventional studies are required to determine whether
replacing third-generation cephalosporins with fluoro-
quinolones will be effective in reducing cephalosporin
resistance and the effect of such interventions on fluoro-
quinolone resistance.
R
esistance to third-generation cephalosporins in gram-
negative nosocomial pathogens is a formidable prob-
lem, associated with adverse clinical outcomes and
increased hospital costs (1–4). Measures to combat the
emergence and spread of resistant nosocomial pathogens
have met with varying degrees of success. Although good
infection control practices are the most important measure
in limiting the spread of resistance, other measures are
required, including changes in antimicrobial drug–pre-
scribing patterns through formulary modification and
enhanced education of prescribers (5). 
Kaye et al. reported a protective effect of fluoro-
quinolone use against the emergence of resistance to third-
generation cephalosporins in nosocomial isolates of
Enterobacter (6). In our study, we aimed to determine
whether this protective effect is translated into an ecologic
phenomenon by using individual patient-level data, i.e.,
whether fluoroquinolone use, in addition to lowering the
likelihood of emergence of resistance in an individual
patient, also results in reduced initial isolation of resistant
strains in a given population. In addition, we aimed to
determine whether the effect of fluoroquinolone use on
Enterobacter spp. is applicable to other gram-negative
pathogens. We conducted a matched case-control study to
test the protective effect of fluoroquinolone use on the sub-
sequent isolation of the three most common gram-negative
hospital pathogens that are resistant to third-generation
cephalosporins, Enterobacter spp., Pseudomonas aerugi-
nosa, and Klebsiella pneumoniae (4).
Methods
Hospital Setting, Study Design, and Microbiology
During the study period, Beth Israel Deaconess
Medical Center, West Campus, was a 320-bed, urban, ter-
tiary-care teaching hospital, with 24 intensive care unit
beds and approximately 12,000 admissions annually; the
hospital serves a nonobstetric adult population in Boston,
Massachusetts. Data were collected from administrative,
laboratory, and pharmacy databases within this hospital by
using relational database software (Access97, Microsoft,
Redmond, WA). The microbiology database was searched
to identify all cultures positive for nosocomial third-gener-
ation cephalosporin-resistant Enterobacter spp., P. aerugi-
nosa,  and  K. pneumoniae in hospitalized patients from
October 1, 1993, to June 1, 1998. To qualify for inclusion,
an isolate had to grow from a culture taken no earlier than
the host patient’s second hospital day. For Enterobacter
spp. and K. pneumoniae, third-generation cephalosporin
resistance was defined as an MIC of ceftriaxone or cef-
tazidime of >16 µg/mL; resistance in P. aeruginosa was
defined as an MIC of ceftazidime of >16 µg/mL. 
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Hospital, Baltimore, Maryland, USA.Patients whose clinical culture data demonstrated an
isolate with the above criteria were considered case-
patients. A patient could be included only once. To meet
the criteria of appropriate selection of the reference group,
which require that controls be derived from the same
source population that gives rise to the cases (7), controls
were selected randomly from hospitalized patients who did
not have a positive culture for the studied organisms.
Controls were matched to the cases in a 2:1 ratio on the
basis of length of hospital stay until the positive culture
was taken; thus at the time of matching, each control had
been hospitalized as long as his or her index case-patient.
This length of stay was characterized as the risk period.
Variables studied included patient demographics (age
and sex), coexisting conditions  (number of conditions,
AIDS, diabetes mellitus, cardiovascular disease, hepatic
disease, pulmonary disease, renal disease, and malignan-
cy), hospital events during the risk period (surgery, inten-
sive care unit stay), and receipt before the day of culture,
for at least 24 hours, of an agent from any of the following
antimicrobial drug classes: β-lactam/β-lactamase inhibitor
combinations (mostly ampicillin/sulbactam and pipera-
cillin/tazobactam), aminoglycosides (mostly gentamicin
and tobramycin), first- or second-generation cephalo-
sporins, third-generation cephalosporins (mostly ceftriax-
one and ceftazidime), imipenem, ureidopenicillins (mostly
piperacillin), and fluoroquinolones (mostly ciprofloxacin
and ofloxacin). The route of administration of the antimi-
crobial agents was not considered, since the route was par-
enteral for all classes studied except fluoroquinolones. For
fluoroquinolones, the nearly equivalent bioavailability
between the oral and parenteral routes obviated the need to
distinguish patients who received agents from this class
orally from those who received them parenterally. 
Statistical Analysis
Statistical analyses were performed by using SAS soft-
ware (SAS Institute, Inc., Cary, NC, version 8e). Matched
analyses were conducted by using a conditional logistic
regression model. Variables with a p value of <0.05 on uni-
variate matched analysis were included in a multiple con-
ditional logistic regression model. Effect modification
between factors was searched for by testing appropriate
interaction terms for statistical significance. Effect esti-
mates in the regression model were reported as hazard
ratios; p values of <0.05 were considered significant.
Results
Demographics, Coexisting Conditions, 
and Hospital Events
Two hundred eighty-two patients with third-generation
cephalosporin-resistant nosocomial target pathogens were
enrolled in the study: Enterobacter spp. were isolated from
203 patients, P. aeruginosa from 50, and K. pneumoniae
from 29. For all but two of these case-patients, two
matched controls were enrolled per case; for each of the
remaining two, one control was enrolled. Thus, 562
matched controls were included. Median length of stay
before enrollment in the study was 12 days. Case-patients
and controls were similar in age (mean 62.4 vs. 62.1 years;
p = 0.82) and sex distribution (55.3% vs. 52.7% male; p =
0.44). Characteristics of the study patients and the matched
univariate comparisons for case-patients and controls are
summarized in Table 1. Case-patients had a significantly
higher number of coexisting conditions than controls (haz-
ard ratio [HR] 1.22; p = 0.01); specifically, case-patients
had a higher prevalence of hepatic disease (HR 1.70; p =
0.004), pulmonary disease (HR 1.52; p = 0.04), and renal
disease (HR 1.71; p = 0.003). Case-patients were signifi-
cantly more likely than controls to have been in an inten-
sive care unit (HR 2.65; p < 0.001) and to have had surgery
(HR 2.03; p < 0.001) during the risk period.
Antimicrobial Drug Exposures
In the univariate analysis, case-patients were signifi-
cantly less likely than controls to have received a fluoro-
quinolone (HR 0.48; p = 0.008). Case-patients were signif-
icantly more likely than controls to have received a β-lac-
tam/β-lactamase inhibitor (HR 2.48; p < 0.001), a first- or
second-generation cephalosporin (HR 1.39; p = 0.04), a
third-generation cephalosporin (HR 2.98, p < 0.001), or a
ureidopenicillin (HR 2.91, p < 0.001). There was also a
trend toward greater use of aminoglycosides (HR 1.39; p =
0.09) and imipenem (HR 1.51; p = 0.14) in case-patients,
but these associations did not achieve significance. 
Multivariable Analysis
Results of the multivariable analysis are summarized in
Table 2. Neither the total number of coexisting conditions
nor the frequency of any individual condition was signifi-
cantly different between cases and controls. After control-
ling for confounding variables, however, both hospital
events examined (surgery and intensive care unit expo-
sure) remained significantly associated with the isolation
of a resistant gram-negative organism (HR 1.62; p = 0.005,
and HR, 2.17; p < 0.001, respectively). Three antimicro-
bial drug classes remained significantly associated with
isolation of a resistant pathogen: β-lactam/β-lactamase
inhibitor combinations (HR, 2.52; p < 0.001), ureidopeni-
cillins (HR, 2.55; p = 0.002), and third-generation
cephalosporins (HR, 2.84; p < 0.001).
The only factor protective against isolation of a third-
generation cephalosporin-resistant gram-negative
pathogen was exposure to a fluoroquinolone. After con-
trolling for confounding, the protective effect was even
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0.005). Subgroup analyses that used the same multivari-
able model showed a similar protective effect for fluoro-
quinolones against isolation of each of the three pathogens
considered individually, though in the smaller two sub-
groups the results did not achieve significance. 
Confounding by severity of illness was controlled for in
the analysis by the inclusion in the final model of intensive
care unit stay and surgery before culture, as both of these
hospital events, particularly the former, are markers of dis-
ease severity. None of the individual coexisting conditions
analyzed, nor the total number of such conditions, differed
significantly between cases and controls on univariate
analysis, and thus they were not included in the final
model. Moreover, forcing the term for total coexisting con-
ditions into the multivariable model expressly to control
for confounding did not change the results for any of the
significant terms.
Interaction terms between the following factors were
analyzed: fluoroquinolone use and cephalosporin use, sur-
gery and intensive care unit exposure, fluoroquinolone use
and diabetes mellitus, and fluoroquinolone use and renal
disease. None of these interaction terms achieved signifi-
cance, and thus they were not included in the final model.
Discussion
Resistance to third-generation cephalosporins among
gram-negative nosocomial pathogens is associated with
increased mortality, length of stay, and hospital costs
(1–4). Measures to reduce the extent of resistance are
therefore warranted. 
This study was designed to test the hypothesis that
recipients of fluoroquinolones are protected against infec-
tion and colonization with the three most common third-
generation cephalosporin-resistant gram-negative nosoco-
mial pathogens, Enterobacter spp., P. aeruginosa, and K.
pneumoniae (4). We have demonstrated a protective effect
of fluoroquinolone use on infection or colonization with
these resistant organisms both in crude analysis and after
control for confounding variables. Moreover, subgroup
analysis demonstrated this protective effect for each genus
individually, though small numbers of patients with cul-
RESEARCH
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Table 1. Characteristics of study patients and univariate analysis of outcome  
Characteristic  Case-patients (n = 282) (%)  Controls (n = 562) (%)  HR (95% CI)
b  p 
Mean age (y)  62.4  62.1  1.00 (0.99 to 1.01)  0.82 
Male  156 (55.3)  296 (52.7)  1.12 (0.84 to 1.50)  0.44 
No. of coexisting conditions  0:14 (5.0)  0:47 (8.4) 
  1:71 (25.2)  1:155 (27.6) 
  2:111 (39.4)  2:228 (40.6) 
  >3:86 (30.5)  >3:132 (23.5) 
1.22 (1.04 to 1.44)  0.01 
AIDS  1 (0.4)  13 (2.3)  0.15 (0.02 to 1.18)  0.07 
Cardiovascular disease  205 (72.7)  404 (71.9)  1.04 (0.80 to 1. 43)  0.81 
Diabetes mellitus  124 (44.0)  259 (46.1)  0.92 (0.69 to 1.23)  0.57 
Hepatic disease  66 (23.4)  86 (15.3)  1.70 (1.18 to 2.44)  0.004 
Pulmonary disease  48 (17.0)  67 (11.9)  1.52 (1.01 to 2.28)  0.04 
Renal disease  68 (24.1)  88 (15.7)  1.71 (1.20 to 2.44)  0.003 
In intensive care unit during risk period   161 (57.1)  207 (36.8)  2.65 (1.91 to 3.68)  < 0.001 
Malignancy  46 (16.3)  92 (16.4)  0.99 (0.67 to 1.47)  0.97 
Surgery during risk period   164 (58.2)  229 (40.8)  2.03 (1.50 to 2.73)  < 0.001 
Receipt of β-lactam/ β-lactamase inhibitor  111 (39.4)  125 (22.2)  2.48 (1.77 to 3.49)  < 0.001 
Receipt of aminoglycoside  62 (22.0)  97 (17.3)  1.39 (0.95 to 2.04)  0.09 
Receipt of 1st- or 2nd-generation cephalosporin  117 (41.5)  195 (34.7)  1.39 (1.01 to 1.92)  0.04 
Receipt of 3rd-generation cephalosporin  114 (40.4)  122 (21.7)  2.98 (2.07 to 4.27)  < 0.001 
Receipt of imipenem  27 (9.6)  37 (6.6)  1.51 (0.87 to 2.62)  0.14 
Receipt of ureidopenicillin  42 (14.9)  32 (5.7)  2.91 (1.77 to 4.77)  < 0.001 
Receipt of fluoroquinolone  23 (8.2)  79 (14.1)  0.48 (0.28 to 0.82)  0.008 
aOutcome refers to the isolation of third-generation cephalosporin-resistant Enterobacter spp., Pseudomonas aeruginosa, or Klebsiella pneumoniae from a clinical specimen. 
bHR, hazard ratio; CI, confidence interval. 
Table 2. Multivariable analysis of outcome
a 
Characteristic    HR (95% CI)
b  p 
Surgery during risk period  1.62 (1.16 to 2.25)  0.005 
In intensive care unit during risk period  2.17 (1.49 to 3.16)  <0.001 
Receipt of β-lactam/ β-lactamase inhibitor  2.52 (1.67 to 3.80)  <0.001 
Receipt of ureidopenicillin  2.55 (1.43 to 4.53)  0.002 
Receipt of 3rd-generation cephalosporin  2.84 (1.89 to 4.27)  <0.001 
Receipt of fluoroquinolone  0.40 (0.21 to 0.76)  0.005 
aOutcome refers to the isolation of third-generation cephalosporin-resistant Enterobacter spp., Pseudomonas aeruginosa, or Klebsiella pneumoniae from a clinical specimen. 
bHR, hazard ratio; CI, confidence interval. tures positive for P. aeruginosa and K. pneumoniae pre-
cluded statistical significance in these groups, due to the
limited power associated with subgroup analysis. Other
notable findings are that surgery, intensive care unit stay,
and receipt of a β-lactam/β-lactamase inhibitor combina-
tion, a ureidopenicillin, or a third-generation cepha-
losporin increase the likelihood of recovery of these resist-
ant pathogens. Although we did not match case-patients
and controls based on date of admission, division of the
entire study period into three time intervals showed the
ratio of cases to controls to be approximately the same in
each. The likelihood of spurious associations resulting
from disparity between the year of hospitalization of cases
and controls is therefore minimal.
Our analysis did not differentiate between infection and
colonization with the pathogens studied. Since the focus of
the study was the occurrence of third-generation
cephalosporin-resistant nosocomial organisms in the pop-
ulation we studied, this distinction was not necessary. The
organisms we studied are capable of causing infection in a
given patient at any point after colonization. Moreover,
once they have colonized a patient, they are capable of
transmission to other hospitalized patients, in whom they
can cause infection. Our objective, then, was not to com-
pare rates of active disease between hospitalized groups,
but rather to use the recovery of these organisms as a
marker for actual or potential disease in the populations we
examined.
In addition to infection control measures, such as active
surveillance, hygiene, and isolation precautions, the other
important strategy in checking the emergence and spread of
antimicrobial resistance is the manipulation of selective
antimicrobial pressure through changes in use of antimi-
crobial drugs (5). Previous studies exploring the effect of
antibiotics on third-generation cephalosporin resistance
focused on replacement of cephalosporins with other β-lac-
tam–containing agents (8–11). No interventions involving
a substitution with a fluoroquinolone have been reported. 
Two main categories of β-lactamases mediate resist-
ance to third-generation cephalosporins among the com-
mon gram-negative nosocomial pathogens: chromosomal
β-lactamases and plasmid-associated extended-spectrum
β-lactamases (ESBLs) (12). Enzymes that can confer
resistance to most penicillins, cephalosporins, and
monobactams, ESBLs belong to Bush-Jacoby-Medeiros
functional group 2, whose enzymes are generally inhibited
in vitro by β-lactamase inhibitors. By contrast, the chro-
mosomal  β-lactamases present in Enterobacter and
Pseudomonas (which constitute 90% of the resistant iso-
lates in our study) belong to group 1, whose enzymes are
not inhibited by β-lactamase inhibitors (13).
Earlier studies described interventions carried out when
plasmid-associated ESBLs were the main mechanism of
resistance, so it is not surprising that replacing
cephalosporins with a β-lactam/β-lactamase inhibitor
combination, as was done in some of these studies
(8,9,11), resulted in reduced rates of cephalosporin resist-
ance. Our study, by contrast, found both ureidopenicillins
and  β-lactam/β-lactamase inhibitor combinations to be
risk factors for the isolation of gram-negative organisms
resistant to third-generation cephalosporins. We believe
that this discrepancy relates to the fact that the predomi-
nant cause of resistance in our hospital during the study
period was group 1 chromosomal β-lactamases (against
which β-lactamase inhibitors are not active) and that plas-
mid-mediated ESBLs played only a minimal role (14).
Our findings expand on the observations of Kaye et al.
regarding the protective effect of fluoroquinolones on the
emergence of third-generation cephalosporin-resistant
Enterobacter spp (6). They diverge, however, regarding
risk factors. Although Kaye et al. found third-generation
cephalosporin exposure to be an independent risk factor
for emergence of resistance, no other antimicrobial expo-
sure or hospital event was independently associated with
this finding. We propose that the suggested discrepancy
between these results and our findings that certain hospital
events and antimicrobial classes confer enhanced risk for
initial isolation of resistant organisms can be attributed to
the difference in the design of the two studies.
Kaye et al., in examining emergence of resistance,
identified clinical isolates for which β-lactamase produc-
tion was induced or derepressed mutants were selected.
Our study design, by contrast, detected those patients col-
onized or infected by an organism with preexisting third-
generation cephalosporin resistance, a phenomenon made
more likely by certain hospital events or antimicrobial
drug exposures. Whereas Kaye’s case-patients began with
susceptible isolates that developed resistance after a spe-
cific exposure, our case-patients were enrolled with
already resistant strains. Thus, while a particular hospital
event or antimicrobial drug exposure may not induce β-
lactamase production or select derepressed mutants, it
may well confer enhanced susceptibility to the acquisition
of a strain in which resistance mechanisms are already
expressed.
Although we do not include molecular typing or epi-
demiologic data regarding patterns of antimicrobial drug
use and colonization with resistant organisms, earlier stud-
ies conducted during our study period at the same institu-
tion have answered many of these questions (14,15). These
studies showed that colonization with ceftazidime-resist-
ant gram-negative bacilli in intensive care units during a
nonoutbreak period was common, was probably acquired
before admission to the unit, involved diverse strains, and
was associated with prior exposure to a variety of β-lactam
antimicrobial drugs. 
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third-generation cephalosporins with other agents are not
readily generalizable as they are prone to several possible
biases: 1) they are before/after studies and are therefore
prone to time effect bias; 2) they describe a group-level
analysis and are therefore prone to ecologic bias (16); 3)
the formulary intervention is usually coupled with
improved infection control measures, causing difficulty in
determining which measure is responsible for the noted
effect; and 4) these studies are more likely to be reported
and published when a positive effect is noted, i.e., pub-
lication bias. 
Our data as well as those of Kaye et al. suggest that flu-
oroquinolones could be substituted for certain types of β-
lactam antimicrobial drugs to prevent the emergence and
lower the rates of isolation of the most common third-gen-
eration cephalosporin-resistant gram-negative nosocomial
pathogens. The potential advantages of adding fluoro-
quinolones to the armamentarium of agents that can be
used to combat third-generation cephalosporin resistance
are several: they can be administered orally; they are rela-
tively nontoxic and inexpensive; and they may allow the
replacement of earlier generation cephalosporins, receipt
of which has previously been identified as a risk factor for
isolation of third-generation cephalosporin-resistant gram-
negative organisms (15). 
A limitation of retrospective analyses is the inability to
prove what appear to be causal relationships. Statistical
associations are interpreted as risk factors, and inverse
associations as protective effects. Proof that fluoro-
quinolones are in fact protective against the isolation of
nosocomial third-generation cephalosporin-resistant gram-
negative pathogens, as suggested by the inverse associa-
tion demonstrated here, will require animal models or
prospective interventional studies. Such studies will also
be required to determine whether reduced third-generation
cephalosporin resistance will come at the cost of increased
levels of fluoroquinolone resistance, a phenomenon to
which Burke has referred as “squeezing the balloon” (17).
Fluoroquinolone resistance, not addressed in our study,
occurs primarily by means of chromosomal mutation (18),
and resistant mutants could potentially be selected for by
increased use of this class of antimicrobial agent. Our data,
then, provide the impetus for further studies, including a
prospective interventional trial to explore the overall pro-
tective efficacy of fluoroquinolones against multiresistant
gram-negative pathogens.
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